Form 4 for CMPX Compass Therapeutics, Inc.
Accepted 2023-11-21 00:00:00 ET · period of report 2023-11-17 · accession 0001171843-23-007223 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-21 | 2023-11-17 | CMPX | Bisker-Leib Vered | COO | F - Tax | $1.50 | -64.4K | 1.42M | -4% | -$96.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-17 | F | D | 64,415 | $1.50 | 1,420,499 | D | — | — | (F2) 8,148 of these shares of common stock underlie unvested restricted stock awards that are subject to a right of repurchase in favor of the issuer, which will vest on November 30 and December 31, 2023. 300,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on November 16, 2021. 400,000 of the shares represents unvested restricted stock units ("RSU") granted to the reporting person on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on November 15, 2022. |